{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:40:27Z","timestamp":1780666827985,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The fluoroquinolone antimicrobial agents, enrofloxacin and marbofloxacin, were approved in the United States for cats in 1990 and 2001, respectively. In 2023, revised breakpoints for testing isolates from dogs were published. These canine breakpoints are discordant with the current feline breakpoints. This study was aimed at suggesting new feline breakpoints using a pharmacokinetic\u2010pharmacodynamic (PK\u2010PD) approach and new pharmacokinetic data. The PK\u2010PD derived cutoff values (CO\n                    <jats:sub>PD<\/jats:sub>\n                    ) were compared to microbiologic data available for testing the susceptibility of targeted pathogens since the original approval. Compared to the current Clinical and Laboratory Standards Institute (CLSI) breakpoints for enrofloxacin and marbofloxacin in cats, these revised breakpoints are lower by two dilutions for the Enterobacterales,\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">Pseudomonas aeruginosa<\/jats:styled-content>\n                      , Staphylococcus\n                    <\/jats:italic>\n                    spp., and\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>Pasteurella multocida<\/jats:italic>\n                    <\/jats:styled-content>\n                    . Isolates that may have previously tested susceptible (S) may test resistant (R) using these suggested breakpoints. We also are suggesting a susceptible dose\u2010dependent (SDD) category for testing marbofloxacin against these isolates from cats that allows for a higher dose. These suggested breakpoints may be considered by laboratories, standard\u2010setting organizations, and industry sponsors of these antimicrobials for testing common bacteria isolated from cats.\n                  <\/jats:p>","DOI":"10.1111\/jvp.70028","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:20:51Z","timestamp":1759152051000},"page":"131-140","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Need for a Revision of Fluoroquinolone Breakpoints for Interpretation of Antimicrobial Susceptibility Testing of Feline Bacterial Isolates"],"prefix":"10.1111","volume":"49","author":[{"given":"Mark G.","family":"Papich","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine North Carolina State University  Raleigh North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacie A.","family":"Gunnett","sequence":"additional","affiliation":[{"name":"Zoetis  Kalamazoo Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4512-853X","authenticated-orcid":false,"given":"Marilyn N.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Center for Veterinary Medicine, US Food and Drug Administration  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2004.05.011"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2006.26.1.129"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa084"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2005.00664.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2011.08.015"},{"issue":"1","key":"e_1_2_10_7_1","first-page":"87","article-title":"Protein Binding of Pradofloxacin, a, Novel 8\u2010Cyanofluoroquinolone, in Dog and Cat Plasma","volume":"26","author":"Bregante M. A.","year":"2003","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"e_1_2_10_8_1","volume-title":"Development of Quality Control Ranges, Breakpoints, and Interpretive Categories for Antimicrobial Agents Used in Veterinary Medicine","author":"CLSI","year":"2021"},{"key":"e_1_2_10_9_1","volume-title":"Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals","author":"CLSI","year":"2024"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12886"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro862"},{"key":"e_1_2_10_12_1","unstructured":"European Committee on Antimicrobial Susceptibility Testing.2020. Data From the EUCAST MIC Distribution Website Last Accessed 03 Jul 2024.http:\/\/www.eucast.org."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.16866"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2448"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/rvsc.2001.0466"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jam.13287"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9020014"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05360\u201011"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.13498"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2016.05.020"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jam.14274"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2016.0110"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.23.07.0159"},{"key":"e_1_2_10_24_1","first-page":"152","article-title":"Validation of a Therapeutic Regimen for Enrofloxacin in Cats on the Basis of Pharmacokinetic Data","volume":"20","author":"Richez P.","year":"1997","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.2004.65.350"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13060500"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12929"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-06"},{"key":"e_1_2_10_29_1","unstructured":"USCAST The National Antimicrobial Susceptibility Testing Committee for the United States.2018.\u201cQuinolone In\u00a0Vitro Susceptibility Test Interpretive Criteria Evaluations. Version 1.3.\u201dhttp:\/\/www.uscast.org."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02072-18"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.70028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvp.70028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.70028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:33:59Z","timestamp":1773034439000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.70028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/jvp.70028"],"URL":"https:\/\/doi.org\/10.1111\/jvp.70028","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"2024-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}